

Biochemical and Genetic Insights into Asukamycin Biosynthesis^{*[5]}

Received for publication, March 31, 2010, and in revised form, May 25, 2010. Published, JBC Papers in Press, June 3, 2010, DOI 10.1074/jbc.M110.128850

Zhe Rui[‡], Kateřina Petříčková[§], František Škanta[§], Stanislav Pospíšil[§], Yanling Yang[‡], Chung-Yung Chen[¶], Shih-Feng Tsai^{||}, Heinz G. Floss^{**}, Miroslav Petříček^{§1}, and Tin-Wein Yu^{‡2}

From the [‡]Department of Biological Science, Louisiana State University, Baton Rouge, Louisiana 70803, the [§]Institute of Microbiology AS CR, Vídeňská 1083, 142 20 Prague 4, Czech Republic, the [¶]Department of Bioscience Technology, Chung Yuan Christian University, Chung Li 32023, Taiwan, the ^{||}Institute of Genetics, National Yang-Ming University, Taipei 112, Taiwan, and the ^{**}Department of Chemistry, University of Washington, Seattle, Washington 98195

Asukamycin, a member of the manumycin family metabolites, is an antimicrobial and potential antitumor agent isolated from *Streptomyces nodosus* subsp. *asukaensis*. The entire asukamycin biosynthetic gene cluster was cloned, assembled, and expressed heterologously in *Streptomyces lividans*. Bioinformatic analysis and mutagenesis studies elucidated the biosynthetic pathway at the genetic and biochemical level. Four gene sets, *asuA–D*, govern the formation and assembly of the asukamycin building blocks: a 3-amino-4-hydroxybenzoic acid core component, a cyclohexane ring, two triene polyketide chains, and a 2-amino-3-hydroxycyclopent-2-enone moiety to form the intermediate protoasukamycin. AsuE1 and AsuE2 catalyze the conversion of protoasukamycin to 4-hydroxyprotoasukamycin, which is epoxidized at C5–C6 by AsuE3 to the final product, asukamycin. Branched acyl CoA starter units, derived from Val, Leu, and Ile, can be incorporated by the actions of the polyketide synthase III (KSIII) AsuC3/C4 as well as the cellular fatty acid synthase FabH to produce the asukamycin congeners A2–A7. In addition, the type II thioesterase AsuC15 limits the cellular level of ω -cyclohexyl fatty acids and likely maintains homeostasis of the cellular membrane.

The metabolites of the manumycin family are known to have a broad range of antibiotic functions including antibacterial, anticoccidial, and antifungal activities (1). Manumycin compounds also display a strong activity against farnesyltransferase, I κ B kinase β , interleukin-1 β -converting enzymes, and acetylcholinesterase and are considered as drug candidates to treat cancers, inflammation, and Alzheimer disease (1–4). Asukamycin A1, a manumycin-type metabolite, contains a unique

2-amino-4-hydroxy-5,6-epoxycyclohex-2-enone (mC₇N)³ core and two *trans*-triene polyketide chains, in which the upper one starts with a cyclohexane ring, and the lower one terminates in the five-membered ring of a 2-amino-3-hydroxycyclopent-2-enone (C₅N) moiety (Fig. 1) (5). Asukamycin, together with a series of congeners A2–A7 carrying branched alkyl groups in place of the cyclohexane moiety, were isolated from *Streptomyces nodosus* subsp. *asukaensis* (6–8). Like in a majority of the manumycin-type metabolites, the C5,C6 epoxy group can be reduced to a 5-hydroxyethylene structure enzymatically or nonenzymatically to form the type II asukamycins, B1–B5 (Fig. 1) (8). The epoxide group of the manumycins is considered crucial for many biological functions, as the type II products show weaker activities (1).

Based on precursor feeding experiments, the asukamycin mC₇N core unit and the cyclohexane moiety originate from 3-amino-4-hydroxybenzoic acid (3,4-AHBA) and shikimic acid, respectively (9–11). The identical lower and upper triene polyketide chains are built up from 3,4-AHBA and cyclohexyl-carbonyl CoA (CHC-CoA), respectively, by three steps of classical polyketide condensations. A gene set involved in the CHC-CoA biosynthesis of ansatrienin has been well characterized in *Streptomyces collinus* (12), but the genes involved in 3,4-AHBA and polyketide chain assembly of asukamycin have not been identified. The C₅N ring moiety, found in several natural products including reductionmycin, moenomycin A, and ECO-02301, was suggested to be derived from a 5-aminolevulinate (5-ALA) intermediate (13–16). The only reported gene product of *asuD2* (*hemA-asuA*), a member of the 2-oxoamine synthases, was found to be involved in asukamycin biosynthesis and to catalyze the condensation of succinyl-CoA and glycine (15). Protoasukamycin C1, the polyketide assembly product, is further oxygenated to give the final product asukamycin (1, 10, 17). The upper polyketide chain assembly of the congeners A2–A7 recruits the branched acyl CoA starters, which are predominantly used for fatty acid biosynthesis in *S. nodosus* subsp. *asukaensis* (7). Alternatively, the CHC-CoA starter of asukamycin


^{*} This work was supported, in whole or in part, by National Institutes of Health Grant CA76461 (to T.-W. Y.). This work was also supported by Czech Ministry of Education Grant 2B06154, Institutional Scientific Program AV0Z50200510 (to M. P.), a Louisiana State University Faculty Startup Fellowship (to T.-W. Y.), and a Louisiana State Economic Development Assistantship (to T.-W. Y. and Z. R.).

^[5] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental text, Tables S1–S3, and Figs. S1–S6.

¹ To whom correspondence may be addressed: Inst. of Microbiology AS CR, Vídeňská 1083, 142 20 Prague 4, Czech Republic. Fax: 420-24106-2347; E-mail: petras@biomed.cas.cz.

² To whom correspondence may be addressed: 678 Life Science Bldg., Louisiana State University, Baton Rouge, LA 70803. Fax: 225-578-2597; E-mail: tin.laorchid@gmail.com.

³ The abbreviations used are: mC₇N, 2-amino-4-hydroxy-5,6-epoxycyclohex-2-enone; 3,4-AHBA, 3-amino-4-hydroxybenzoic acid; C₅N, 2-amino-3-hydroxycyclopent-2-enone; 5-ALA, 5-aminolevulinate; ACP, acyl carrier protein; FAS, fatty acid synthase; ALAS, 5-aminolevulinate synthase; CHC, cyclohexylcarbonyl; HPLC, high pressure liquid chromatography; LC-MS, liquid chromatography-mass spectrometry; KS, polyketide synthase; PDB, Protein Data Bank.



A8, B8, C8 = -COCH₃ in place of upper polyketide chain

A1a-A5a, B1a-B5a = A1-A5, B1-B5 with -OH in place of C₅N unit

FIGURE 1. Structures of asukamycin and related metabolites. Compounds are grouped according to the main A, B, C, and D core units.

polyketide chain assembly can also be used to form ω -cyclohexyl fatty acids as a part of cellular membrane components. As the membrane fluidity and permeability are strongly determined by the fatty acid composition, the biosynthetic regulation of each fatty acid component is crucial for membrane homeostasis in bacteria (18, 19). The content of ω -cyclohexyl fatty acids, a byproduct generated during the peak period of asukamycin biosynthesis, is maintained to be as low as 3% (7). This implies that the organism has a control mechanism to balance the metabolic flux between the production of membrane fatty acids and asukamycin. Herein, we report the cloning, mutagenic analysis, and characterization of the biosynthetic genes, which provides insight into the biosynthetic assembly of the asukamycins in *S. nodosus* subsp. *asukaensis*. Possible cross-talk between the biosynthesis of the fatty acids and the asukamycins is also discussed.

EXPERIMENTAL PROCEDURES

Bacterial Strains and Chemicals—*S. nodosus* subsp. *asukaensis* ATCC 29757 was obtained from the American Type Culture Collection. *Streptomyces lividans* K4-114 was kindly provided by Dr. C. Khosla. *Escherichia coli* strains were obtained from the John Innes Center (Norwich, UK). The media and chemicals were purchased from Difco, Sigma-Aldrich, and EMD Chemicals.

Genomic Library and Mutant Construction—See supplemental text.

In Vivo Recombination and Heterologous Expression of the Cloned *asu* Gene Cluster—The cosmids 2B9 and 10D6 were linearized by SpeI and EcoRI, respectively, equally mixed, and transformed into *E. coli* BW25113/pIJ790 competent cells by electroporation (20). The cells were then added to 1 ml of SOC medium (20), recovered at 37 °C for 3 h, and plated out onto LB agar with 100 μ g/ml apramycin. For the negative control, the

linearized 2B9 and 10D6 were transformed separately by the same procedure. The recombinant clone was confirmed by matching the anticipated EcoRI digestion pattern and named pART1361. Intergeneric conjugation of the recombinant cosmids from *E. coli* to *S. lividans* K4-114 followed the established protocol (21).

Construction of pART1391, pART1361E3, and pALS4-S83T—To construct pART1391, a 1.5-kb DNA fragment from pIJ778 was PCR-amplified using primers AsuRED-4 and -6 (supplemental Table S3) to carry a spectinomycin resistance gene cassette plus two 50-bp nucleotides, designed to be identical to the boundaries of the targeted region on pART1361 (supplemental Fig. S5) (20). To obtain the recombinant strain, the gel-purified PCR fragment was

introduced into *E. coli* BW25113/pART1361/pIJ790 by electroporation, and the transformants were screened for spectinomycin resistance. The deletion in the resulting clone was confirmed by matching up to the expected EcoRI digestion pattern and verified by PCR. The pART1361E3 construction followed the same strategy as described above but using primers AsuRED-E3F and -E3R (supplemental Table S3).

To insert the point mutation that modifies the TCC (Ser) codon into ACC (Thr) in the *asuD2* gene, the internal fragment containing the BamHI-KpnI sites was PCR-amplified using primers S83TF and S83TR (supplemental Table S3). The BamHI-KpnI-cleaved fragment was then used to replace the corresponding region in the pALS3 plasmid. The further steps were identical with the pALS4 construction (15).

HPLC and LC-MS Analysis of the Asukamycin Metabolites—*S. nodosus* subsp. *asukaensis*, *S. lividans* K4-114, and the derived strains were cultivated as described (10, 21). Feeding experiments with 3,4-AHBA (100 μ g/ml) and 4-hydroxyprotoasukamycin (20 μ g/ml) were conducted by adding these compounds to 1-day-old cultures and harvesting 1 day later.

Fermented cultures were mixed thoroughly with an equal volume of ethyl acetate. The mixture was separated by centrifugation, and the ethyl acetate layer was collected and evaporated to near dryness. The crude extract was dissolved in an equal volume of methanol and analyzed using a P680 HPLC system (Dionex, Sunnyvale, CA) and an XTerra RP18 column (4.6 \times 250 mm; Waters) at a flow rate of 0.5 ml/min at 25 °C. Twenty μ l of crude extract were injected, equilibrated with 65% solvent B (acetonitrile with 0.1% formic acid) in solvent A (water with 0.1% formic acid) for 5 min, developed with a gradient of 65–90% solvent B in solvent A for 20 min, and washed with 90% solvent B in solvent A for 10 min. To analyze the *asuD1*–*D3* mutants, a gradient of 50–70% solvent B in solvent




FIGURE 2. **Open reading frames identified in the *asu* cluster.** The putative genes were divided into eight groups based on the functional characterization. Group A, 3,4-AHBA biosynthesis and adenylation; Group B, CHC-CoA biosynthesis; Group C, polyketide chain assembly; Group D, C_5N moiety biosynthesis; Group E, oxygenation; Group R, transcriptional regulation. *AsuM1*, efflux protein. The relative genomic regions and overlapping inserts of three cosmid clones, 2B9, 10D6, and pART1391, are indicated with **bold lines**.

A was applied instead. The extraction and HPLC analysis of 3,4-AHBA followed the described protocol (22).

High resolution MS and LC-MS analyses were carried out on a 6210-TOF LC-MS system (Agilent Technologies Inc., Santa Clara, CA) in which the LC was performed using a XDB C18 (4.6×50 mm, 1.8-micron particle size) high throughput column (Agilent Technologies, Inc.) with the same elution program as the HPLC analysis mentioned above. The exact masses of the identified compounds are listed in [supplemental Table S1](#).

Fatty Acid Analysis—See [supplemental text](#).

Purification and NMR Analysis of *D1*—A reliable yield of the novel intermediate 4-hydroxyprotoasukamycin *D1* was obtained in *S. lividans* K4-114 carrying pART1361E3, which was generated from pART1361 with the λ -Red PCR strategy by replacing *asuE3* with a spectinomycin resistance gene. *S. lividans* K4-114/pART1361E3 was inoculated into 500 ml of MS medium in 2-liter flasks with a coil and fermented on a rotary shaker at 250 rpm and 28 °C for 4–5 days. One liter of harvested culture was extracted three times with an equal volume of ethyl acetate, and the combined ethyl acetate extract was dried, concentrated, and purified on a silica gel column (100–200 mesh), eluting with dichloromethane/methanol (100:3). The compound *D1* fraction was collected and further purified by semi-preparative C18 reverse phase HPLC (Dionex), eluting with 75–85% solvent C (methanol with 0.1% formic acid) in solvent A, to give 20 mg of pure compound *D1*. Its 1H -NMR, ^{13}C -NMR, HSQC, and HMBC spectra were recorded in Me_2SO-d_6 on a Varian System 700 spectrometer ([supplemental Table S2](#)).

Purification and NMR Analysis of *B8*—The *asuC2* mutant was inoculated into 50 ml of YMG medium in 250-ml flasks with coils and fermented at 250 rpm and 28 °C for 3 days. One liter of harvested culture was extracted three times with an equal volume of ethyl acetate. The combined ethyl acetate extract was dried, concentrated, and purified on a silica gel column (100–200 mesh), eluting with dichloromethane/methanol (90:10). The compound *B8* fraction was further purified by semi-preparative C18 reverse phase HPLC (Dionex), and eluting with 35–50% solvent C in solvent A, and 2 mg of pure compound *B8* was obtained. 1H NMR (700 MHz, Me_2SO-d_6) δ_H 8.91 (s, 1H, NH-14), 8.88 (s, 1H, NH-0'), 7.27 (d, 1H, $J = 7.8$ Hz, H-3), 7.12 (dd, 1H, $J = 15.0, 11.5$ Hz, H-11), 6.67 (dd, 1H, $J = 15.1, 10.9$ Hz, H-9), 6.47 (dd, 1H, $J = 15.2, 11.0$ Hz, H-10), 6.43

(dd, 1H, $J = 14.9, 11.5$ Hz, H-8), 6.38 (d, 1H, $J = 15.0$ Hz, H-12), 6.12 (d, 1H, $J = 15.2$ Hz, H-7), 3.85 (m, 1H, H-5), 2.71 (dd, 1H, $J = 16.8, 3.2$ Hz, H-6_{ax}), 2.59 (dd, 1H, $J = 16.5, 6.07$ Hz, H-6_{eq}), 1.90 (s, 3H, H-2'). ^{13}C -NMR (700 MHz, Me_2SO-d_6) δ_C 192.6 (C-1), 169.5 (C-1'), 165.0 (C-13), 140.3 (C-11), 138.8 (C-9), 138.4 (C-7), 131.5 (C-8), 130.8 (C-2), 129.6 (C-3), 129.5 (C-10), 124.5 (C-12), 73.0 (C-4), 71.3 (C-5), 40.1 (C-6), 23.9 (C-2').

RESULTS

Cloning of the *asu* Cluster—To clone the asukamycin biosynthetic gene cluster, a cosmid genomic library of *S. nodosus* subsp. *asukaensis* was constructed and screened with two ^{32}P -labeled DNA probes. *ChcA*, encoding the 1-cyclohexenylcarbonyl CoA reductase of ansatrienin biosynthesis in *S. collinus* (12), identified two cosmids, 2B9 and 10D6, which revealed a 1.8-kb overlapping region of the cloned DNA inserts. *AsuD2*, encoding a 2-oxoamine synthase, hybridized only with cosmid 10D6 (15). Cosmids 2B9 and 10D6 were mapped and sequenced to disclose a total combined 63,922 bp of DNA inserts (GenBankTM accession number GQ926890). DNA sequence analysis revealed 36 potential open reading frames, tentatively assigned as the *asu* genes, encoding gene products potentially involved in asukamycin biosynthesis and regulatory activities (Fig. 2 and Table 1).

Heterologous Expression of the *asu* Cluster—To confirm that the cloned region contains all of the genes in control of asukamycin biosynthesis, regulation, and self-immunity (Table 1), a series of heterologous expression experiments was conducted in the asukamycin nonproducing *S. lividans* K4-114. Because neither 2B9 nor 10D6 carries a full set of the predicted biosynthetic genes, we modified the conventional λ -Red recombination strategy (20, 23–25) and reassembled the cosmids 2B9 and 10D6 into a single clone (Fig. 3). The resulting cosmid pART1361 was introduced into *S. lividans* by conjugation from *E. coli*. Brightly yellowish metabolites were observed in the culture and were confirmed to be asukamycins **A1–A7** by high resolution LC-MS. Cosmid pART1391 was further constructed from pART1361 to eliminate a 25.4-kb left-hand side insert region, in which the identified open reading frames were mainly related to primary metabolic functions in Streptomyces. LC-MS analysis confirmed that *S. lividans* K4-114/pART1391 is fully capable of producing asukamycins **A1–A7** (Fig. 4d). These expression results indicate that the cloned 36 *asu* genes in pART1391 are sufficient for asukamycin production.

TABLE 1

Deduced functions of open reading frames in the asukamycin biosynthetic gene cluster

Protein	Amino acid	Homolog (accession no.)	Identified or proposed function
AsuA1	372	GriH (YP_001825760.1)	3,4-AHBA synthase
AsuA2	471	ACMS I (AAD30111.1)	3,4-AHBA carboxyl group adenylation
AsuA3	278	GriI (BAF36651.1)	Condensation of L-aspartate-4-semialdehyde and dihydroxyacetone phosphate
AsuB1	983	PlmJK (AAQ84158.1)	5-Enolpyruvylshikimate-3-phosphate synthase/CHC-CoA ligase
AsuB2	394	PlmL (AAQ84159.1)	Acyl-CoA dehydrogenase
AsuB3	277	ChcA (AAC44655.1)	1-Cyclohexenylcarbonyl CoA reductase
AsuB4	667	PlmM (AAQ84161.1)	2,4-DienoylCoA reductase
AsuC1	219	Sfp (PDB 1QR0)	Phosphopantetheinyl transferase
AsuC2	269	GdmF (AAO06919.1)	Arylamine N-acyltransferase
AsuC3	338	ZhuH (PDB 1MZJ)	Asukamycin ketosynthase III
AsuC4	361	ZhuH (PDB 1MZJ)	Asukamycin ketosynthase III
AsuC5	84	ZhuG (AAG30194.1)	Asukamycin KSIII associated ACP
AsuC6	151	Paal (P76084)	Thioesterase
AsuC7	234	Sco1815 (PDB 2NM0)	Ketoreductase
AsuC8	152	HadC (NP_215151.1)	Acyl dehydratase
AsuC9	150	HadB (YP_001281933.1)	Acyl dehydratase
AsuC10	94	Putative open reading frame	Unknown
AsuC11	91	ZhuN (AAG30201.1)	KSI/II associated ACP
AsuC12	87	AcmACP (AAD30112.1)	3,4-AHBA carrier protein
AsuC13	397	FabF (PDB 2GQD)	Asukamycin ketosynthase I/II
AsuC14	240	FabF (PDB 2GQD)	Asukamycin ketosynthase I/II
AsuC15	260	RifR (PDB 3FLB)	Type II thioesterase
AsuR1	242	GerE (PDB 1FSE)	Transcriptional regulation
AsuR2	191	TetR family protein	Transcriptional regulation
AsuR3	307	Membrane protein	Transcriptional regulation
AsuR4	141	DNA-binding protein	Transcriptional regulation
AsuR5	254	FarR3 (BAG74713.1)	Transcriptional regulation
AsuH1	384	Putative open reading frame	Unknown
AsuR6	280	GerE (PDB 1FSE)	Transcriptional regulation
AsuE1	407	PHBH (PDB 1YKJ)	Protoasukamycin 4-hydroxylase
AsuE2	185	PheA2 (PDB 1RZ0)	Flavin reductase
AsuE3	371	LimB (Q9EUT9.1)	4-Hydroxyprotoasukamycin epoxidase
AsuD1	531	NovL (AAF67505.1)	Amide synthase
AsuD2	409	MoeC4 (ABJ90148.1)	2-Oxoamine synthase
AsuD3	468	MoeA4 (ABJ90146.1)	5-Aminolevulinate CoA ligase
AsuM1	512	EmrB (YP_001507963.1)	Asukamycin exporter




FIGURE 3. Assembly of two cosmids with overlapping inserts. *a*, cosmids 2B9 and 10D6 were linearized by *SpeI* and *XbaI*, respectively. Homologous recombination occurred at two overlapping insert and vector regions, indicated by heavy lines. *b*, the restriction map of 2B9, 10D6, and pART1361. The inserts are shown with solid lines. The *EcoRI* fragment sizes are indicated (kb). *c*, comparison of the *EcoRI* digestion patterns by DNA gel electrophoresis.

3,4-AHBA and Lower Polyketide Chain Formation—Two genes in the cloned *asu* cluster, *asuA1* and *asuA3*, are closely related to the characterized *griH* and *griI*, respectively, which are involved in the assembly of L-aspartate-4-semialdehyde and

dihydroxyacetone phosphate into the grixazone 3,4-AHBA moiety in *Streptomyces griseus* (22). Mutants disrupted in *asuA1* and *asuA3*, respectively, were constructed to confirm their roles in 3,4-AHBA formation. Neither 3,4-AHBA nor asukamycin were detected in the cultures of these mutants, but the addition of 3,4-AHBA restored asukamycin production in both mutants (supplemental Fig. S1a). However, the new minor accumulated products E1 and E3/E4, which possess a C₅N moiety amide-linked with the triene upper chains corresponding to A1 and A3/A4, respectively, were detected by LC-MS analysis (supplemental Fig. S6).

Presumably, 3,4-AHBA is activated by adenylation and then tethered to a specific aryl carrier protein for the downstream chain extensions as in the aromatic polyketide and polypeptide biosynthetic systems employing an aryl carboxylate starter (26–28). *AsuA2* is homologous to the actinomycin synthetase I, which initiates actinomycin formation in *Streptomyces chrysomallus* by activating 4-methyl-3-hydroxyanthranilate (4-MHA) in the presence of ATP (26). The *asuA2* mutant failed to produce any asukamycins but accumulated 3,4-AHBA, as confirmed by HPLC comparison with standard 3,4-AHBA as well as by restoring asukamycin production upon co-culturing with the 3,4-AHBA assembly-deficient *asuA1* mutant (supplemental Fig. S1b). *AsuC11* and *AsuC12* both belong to the acyl carrier protein (ACP) family. *AsuC12* is distinctly related to AcmACP, a specific aryl carrier protein of the actinomycin pathway, which is charged by the priming molecule 4-MHA-AMP and forwards it to the peptide synthase AcmII for chain initiation




FIGURE 4. HPLC analysis of asukamycin metabolites. *a*, 20 μ l of crude culture extract of the *asuB1* mutant. *b*, the *asuC3C4* double mutant. *c*, the *asuC15* mutant. *d*, *S. lividans* K4-114/pART1391. *e*, *S. nodosus* subsp. *asukaensis* wild type strain. The related peaks of asukamycins **A1**–**A5** and **B1**–**B4** are indicated. The y axis indicates the absorbance abundance. Panel *b* was calculated based on a 10 \times injection amount.

(26). The mutant in which both *asuC11* and *asuC12* were truncated showed a similar phenotype as the *asuA2* mutant, *i.e.* 3,4-AHBA accumulation and no asukamycin production (supplemental Fig. S1*b*).

AsuC13 has strong similarity to a group of type II iterative fatty acid synthase (FAS)/polyketide synthase (29, 30). *AsuC13* was confirmed to be a KSI/II polyketide synthase (31, 32) involved in the lower polyketide chain assembly, as the *asuC13* mutant failed to produce any asukamycins and accumulated 3,4-AHBA, similar to the *asuA2* and *asuC11C12* mutants (supplemental Fig. S1*b*). Notably, trace amounts of **E1** and **E3/E4** were also found in this mutant culture as observed in the *asuA1* and *asuA3* mutants. The *asuC14* gene, immediately downstream of *asuC13*, encodes a protein homologous to *AsuC13*, except for a truncated N terminus and lack of the characteristic Cys-His-His catalytic triad. This unusual *asuC13*–*asuC14* pair in which an intact polyketide synthase gene accompanies a partially truncated partner is also found in several uncharacterized gene clusters from the genomic sequencing projects of *Streptomyces hygroscopicus* (ZP_05513707-8) and *Salinispora arenicola* (YP_001535964-5 and YP_001537504-5). Mutation studies are in progress, but the *AsuC14* function remains unknown for the moment. Two additional sequential reactions, a β -keto reduction and a dehydration, are expected for the lower chain assembly. *AsuC7* displays high homology to several polyketide ketoreductases (33, 34). Downstream of *asuC7*, two putative dehydratase genes, *asuC8* and *asuC9*, were found next to each other. *AsuC9* is closely related to *HadB*, which forms a heterodimer with either *HadA* or *HadC* to function in mycolic acid biosynthesis in *Mycobac-*

terium tuberculosis H37Rv (35). Coincidentally, *AsuC8* is highly related to both *HadA* and *HadC*. As *asuC7* and *asuC8,C9* are the only genes in the cluster that could be involved in β -keto reduction and dehydration, we suggest that they operate in the assembly of both the lower and upper *trans*-triene chains.

Upper Polyketide Chain Formation—Unlike other manumycins, formation of the asukamycin upper polyketide chain starts with cyclohexylcarbonyl-CoA (11). Four clustered genes, *asuB1*–*B4*, are homologous to two gene sets, *ansJKLM/chcA* from the ansatrienin producer *S. collinus* and *plmJKLM/chcA* from the phoslactomycin producer *Streptomyces* sp. HK-803, which are involved in CHC-CoA biosynthesis (12, 36). The *asuB1* mutant failed to produce asukamycin, but levels of the previously identified asukamycin congeners **A2**–**A7** were increased 3-fold compared with the wild type strain (Fig. 4*a*). LC-MS analysis further identified three new compounds, **A8**, **B8**, and **C8** (Fig. 1). The NMR analysis of **B8** revealed a **B1**-like structure except that the upper polyketide chain was replaced by an acetyl group. Based on the molecular weight, compounds **C8** and **A8** are likely the proto-form and type I form of **B8**, respectively. These products probably result from the absence of CHC-CoA plus an oversupply of the 3,4-AHBA-lower chain-ACP intermediate.

To initiate fatty acid or polyketide biosynthesis, acyl-CoA starters are recruited and condensed with a (methyl)-malonyl-ACP by the action of fatty acid synthase *FabH* or *KSIII*. This is distinct from the action of *KSI/II*, joining two ACP-bound acyl substrates in the subsequent chain extensions in many microorganisms (29, 30). The adjacent *asuC3* and *asuC4* are homologous to numerous genes encoding bacterial *FabH*s and *KSIII*s including the *zhuH* of *Streptomyces* sp. R1128 (37). Both *AsuC3* and *AsuC4* feature a putative CoA-binding site and a conserved Cys-His-Asn catalytic triad. As *AsuC3* and *AsuC4* are highly similar to each other, we assume that they might act together as a heterodimer to condense CHC-CoA and malonyl-ACP to give a 3-cyclohexyl-3-oxopropanoyl-ACP intermediate for the downstream polyketide chain assembly. Interestingly, a double mutation of *asuC3* and *asuC4* did not completely eliminate asukamycin production. The *asuC3C4* mutant retained 0.9% asukamycin **A1** and 30.0% congeners **A2**–**A7** relative to the wild type strain yield (Fig. 4*b*), possibly because of the functional complementation by the cellular *FabH* of fatty acid biosynthesis. *AsuC5*, presumably organized in the same transcription unit with *asuC3,C4*, is a *zhuG* homolog (38). As *ZhuG* acts together with *ZhuH* to initiate the assembly of the antitumor polyketide R1128 (38), *AsuC5* may play a crucial role in the beginning round of asukamycin upper chain assembly. So far, the *KSI/II* gene(s) required for the second and third round extensions of the upper chain remain to be identified.

Asukamycin C_5N Moiety Formation—Three adjacent genes, *asuD1*, *asuD2*, and *asuD3*, appear to share one transcription unit. *AsuD2*, previously identified as *HemA*–*AsuA*, belongs to a group of pyridoxal phosphate-dependent 2-oxoamine synthases, including 5-aminolevulinate synthase (ALAS), FUM8, L-serine palmitoyltransferase, and 8-amino-7-oxononanoate synthase, which catalyze the decarboxylative condensation between an amino acid and an acyl-CoA (15, 39–42). Despite high overall sequence similarity, *AsuD2* possesses a Ser⁸³

instead of a strictly invariant Thr⁸³ of the ALAS subgroup. AsuD2 functions differently from the reported ALAS forming 5-ALA in many organisms, as no asukamycins were detected in the *asuD2* mutant even in the presence of 5-ALA, but the asukamycin production was restored by reintroducing the plasmid pALS4 carrying the *asuD2* gene (15). The pALS4-S83T with a S83T replacement in *asuD2* was constructed but failed to restore asukamycin production in the *asuD2* truncated mutant (supplemental Fig. S2). Notably, pALS4-S83T complemented a 5-ALA-deficient *gtr* mutant of *Streptomyces coelicolor* A3(2), which can only grow with 5-ALA supplementation. AsuD3, an acyl-CoA ligase, is proposed to act in the C₅N ring formation, since disruption of the homologous *moeA4* in *Streptomyces ghanaensis* led to accumulation of a moenomycin A analog lacking the C₅N moiety (14). AsuD1 is closely related to a group of amide synthases, including SimL for simocyclinone biosynthesis (43, 44). All of the *asuD1*, *D2*, and *D3* mutants failed to produce asukamycin but accumulated a new set of metabolites, **A1a–A5a**, which carry a free carboxyl group in place of the amide-linked C₅N moiety of **A1–A5**, respectively (supplemental Fig. S1c). The corresponding type II compounds, **B1a–B5a**, were also present in all three mutants. Furthermore, the *asuD1–D3* operon was expressed in *S. lividans*, which resulted in attachment of the C₅N moiety to added ferulic acid to form feruloyl-*N*-(3-hydroxycyclopent-2-enolone)acrylamide, whereas no C₅N moiety was detected in the absence of *asuD1*, *D2*, or *D3* (supplemental text and Fig. S2). This confirmed that *asuD1*, *D2*, and *D3* are required and sufficient for C₅N moiety formation.

Attachment of the Upper Polyketide Chain—Asukamycin contains two amide bonds: the linkage between the upper chain and the mC₇N core and the bridge tethering the C₅N moiety to the lower polyketide chain. AsuC2 belongs to the *N*-acyltransferase family (45). An *asuC2* disrupted mutant was constructed to confirm its involvement in the attachment of the upper chain to the 3-amino group of the 3,4-AHBA primed polyketide intermediate. The production of asukamycins **A1–A7** was completely blocked in the *asuC2* mutant. Instead, the *N*-acetylated compounds **A8**, **B8**, and **C8** were accumulated as in the *asuB1* mutant. In view of the functional deficiency of *asuC2*, these shunt products presumably resulted from the action of a cellular arylamine *N*-acetyltransferase, commonly found to detoxify arylamine or arylhydroxylamine metabolites (46).

Oxygenation of Protoasukamycin—*S. parvulus* Tü 64 fermentation under an ¹⁸O₂ atmosphere has demonstrated that the hydroxyl and the epoxide oxygens at C4 and C5–C6 of manumycin A originate from molecular oxygen, by either a two-step process or a dioxygenase mechanism (10, 17). Three distantly located genes, *asuE1*, *asuE2*, and *asuE3*, are possibly involved in the oxygenation reaction(s). AsuE1 is homologous to *p*-hydroxybenzoate hydroxylase, which converts *p*-hydroxybenzoate into 3,4-dihydroxybenzoate in *Pseudomonas aeruginosa* (47). Instead of producing asukamycin, the *asuE1* mutant accumulated protoasukamycin **C1** and its congeners **C2–C5** (supplemental Fig. S1d). AsuE2 is a homolog of the flavin reductase PheA2, which recycles oxidized FAD_{ox} and provides FAD_{red} to its hydroxylase partner PheA1 in the phenol hydroxylation in *Bacillus thermoglucosidasius* A7 (48). The

asuE2 mutant produced asukamycin **A1** in considerably lower yield than the wild type strain but accumulated major amounts of the protoasukamycins **C1–C5** (supplemental Fig. S1d). This implies that AsuE2 is necessary for the full catalytic function of AsuE1 as a two-component flavoprotein hydroxylase.

AsuE3 is highly related to LimB, a limonene 1,2-monooxygenase that generates limonene-1,2-epoxide in *Rhodococcus erythropolis* (49). Instead of the recognized asukamycins, a group of bright yellowish compounds were accumulated by the *asuE3* disrupted mutant (supplemental Fig. S1d). LC-MS analysis of the major peak suggested that one oxygen atom was missing compared with asukamycin **A1**. ¹H, ¹³C, HMBC, and HSQC NMR analysis of the purified compound showed that a double bond at C5–C6 replaces the epoxide group of asukamycin **A1** (supplemental Table S2). This new compound was therefore named as 4-hydroxyprotoasukamycin **D1**. Its congeners **D2–D5** were also detected. **D1** was converted to asukamycin **A1** when fed to the *asuA3* mutant culture, indicating that **D1** is an intermediate that is further epoxidized by AsuE3 in the final step of asukamycin biosynthesis (supplemental Fig. S1a). Since **D1** was absent in the *asuE2* mutant, the epoxidation may not require AsuE2.

Thioesterase Affects the Primed CHC—AsuC15 is closely related to a group of type II thioesterases found in polyketide and nonribosomal peptide biosynthetic gene clusters, including RifR of rifamycin biosynthesis (50). As the yields of the polyketide and polypeptide products were often considerably impaired in the knock-out mutants, type II thioesterases were proposed to restore the acyl or peptidyl carrier protein function by releasing undesirable intermediates, resulting from a priming or processing error (51–54). The *asuC15* mutant produced a normal amount of asukamycin **A1**, yet the yield of the congeners **A2–A7** was significantly reduced (Fig. 4c). Since CHC-CoA is not only a building block of asukamycin but can also form ω -cyclohexyl fatty acids as membrane components in *S. nodosus* subsp. *asuakaensis* (7), we analyzed the fatty acid compositions of the *asuC15* mutant and the wild type strain by GC-MS (supplemental Fig. S3). Notably, 16.5% of ω -cyclohexyl-C₁₇ fatty acid was detected in the *asuC15* mutant, at least 5-fold higher than the 3.1% detected in the wild type strain. Moreover, 1.7% of ω -cyclohexyl-C₁₉ fatty acid, undetectable in the wild type strain, was also found.

Other asu Gene Functions—AsuC6, a hot dog fold thioesterase, presumably functions to hydrolyze the thioester bond and remove the acyl intermediate from the polyketide synthase (55, 56). It could be responsible for **A1a–A5a** accumulation in the *asuD1*, *D2*, and *D3* mutants, which are supposed to be tightly bound to the ACP AsuC11. The *asuC6* mutant has not yet been constructed, and the precise AsuC6 function remains to be clarified. AsuC1, a phosphopantetheinyl transferase, presumably primes the carrier proteins AsuC5, C11, and C12, which are involved in the lower and upper chain biosynthesis. AsuM1, a homolog of numerous antibiotic efflux exporters, could release the synthesized asukamycin products from the cells. *AsuR1–R6*, discretely detected at the two border regions of the cluster, show homology to numerous putative transcriptional regulator genes found in Gram-positive bacteria. AsuR1 and AsuR6 are closely related to the LuxR-type transcriptional reg-




FIGURE 5. **Proposed asukamycin biosynthetic pathway.** The primary metabolite substrates are shown in *squares*. The ACP and aroyl carrier protein are in *capsules*.

ulators (57). AsuR2 is likely a TetR-like transcriptional regulator (58). AsuR3 is a putative integral membrane sensor protein, which could work together with the DNA-binding protein AsuR4 (59). AsuR5 belongs to the *Streptomyces* antibiotic regulatory proteins (60). As many antibiotic biosynthesis gene clusters contain one or multiple regulatory genes, AsuR1–R6 could have regulatory functions to control the asukamycin biosynthetic gene activities. AsuH1 is a putative open reading frame with an unknown function.

DISCUSSION

The structure of asukamycin features two triene polyketide chains connected to a 3,4-AHBA-derived mC₇N core. The upper chain starts with a cyclohexane head group, and the lower one ends with a C₅N structural moiety. In this study, four major groups of *asu* genes were identified to be involved in the structural assembly: AsuA1 and A3 for 3,4-AHBA biosynthesis, AsuB1–B4 for the conversion of shikimate into CHC-CoA, AsuD1–D3⁴ for C₅N unit formation, and the AsuC group for the lower and upper polyketide chain assembly (Fig. 5).

⁴ During the peer review process of this manuscript, the Walsh group reported a study that supports the proposed AsuD1–D3 function in the C₅N moiety formation (62).

Construction of the lower polyketide chain likely requires a set of type II polyketide synthetic enzymes including the KSI/II AsuC13,C14, the polyketide ketoreductase AsuC7, and the DH AsuC8,C9, based on the sequencing and mutagenic analysis. The results indicate that 3,4-AHBA is activated by AsuA2 to form an acyl-AMP and subsequently loaded onto the aroyl carrier protein AsuC12 to initiate the lower polyketide assembly. AsuC13 and AsuC14 are most likely responsible for the initiation and two further rounds of polyketide chain extensions, as the lower chain biosynthesis was abolished in the *asuC13* mutant. The presence of *asuC14* may not be coincidental. AsuC13 and AsuC14 could function together to constrain the growing triene structures and control the polyketide chain length. Further studies on other manumycin biosynthetic genes should provide more clues on the function of *asuC14*. Since *asuC11* is potentially organized in the same transcription unit with *asuC12–C14*, the AsuC11 ACP could be involved in the second and the third rounds of lower chain polyketide extensions.

For the upper chain, AsuC3,C4 likely initiate the condensation between CHC-CoA and malonyl-ACP, resembling the bacterial FabH and other KSIIIs, which are directly primed with an acyl-CoA. In the *asuC3,C4* mutant most asukamycin A1

production was abolished, and levels of the congeners **A2**–**A7** were reduced compared with the wild type. This reflects a possible involvement of the cellular fatty acid synthase FabH, which displays a substrate preference distinct from AsuC3,C4, priming preferentially with branched chain acyl-CoAs rather than CHC-CoA, to give a higher yield of **A2**–**A7** relative to **A1** (7). The involvement of AsuC3,C4 in the second and third chain elongations is less likely, as FabH catalyzes only the first condensation step and passes the resulting 3-ketoacyl-ACP directly to another enzyme complex for further reductions and chain elongations. Given that **E1** and **E3/E4** were found in the *asuC13* mutant, the only recognized KSI/II gene pair, *asuC13,C14*, may not play a role in the upper chain assembly, although both the upper and lower polyketide chains of asukamycin share an identical triene structure. It seems that an unidentified polyketide KSI/II is required to act together with the polyketide ketoreductase AsuC7 and DH AsuC8,C9 to carry out the upper triene polyketide extension. We also cannot rule out the involvement of a cellular FabB/F-like fatty acid synthase, as the successful heterologous expression in *S. lividans* implies that a common KSI/II or FASI/II can fulfill the functional role of this unidentified β -keto condensation enzyme.

The formation of **A1**–**A4** only differs at the priming step of the upper polyketide chain. **A2**–**A4** employ the branched chain amino acid-derived starters 2-methylpropionyl-CoA and 3- and 2-methylbutanoyl-CoA, respectively, which are predominantly used for fatty acid synthesis in *Streptomyces* (7). In the *asuB1* mutant, the absence of CHC-CoA abolished the entire **A1** production and redirected the biosynthetic flux to **A2**–**A4**. Since **A2**–**A4** formation was 10-fold higher in this mutant than in the *asuC3,C4* mutant, the majority of **A2**–**A4** upper polyketide initiation is likely performed by the KSIII AsuC3,C4, and only a minor fraction of **A2**–**A4** production in the *asuB1* mutant as well as the wild type strain is contributed by the FabH activity. The relatively small amount of **A5**–**A7** production could result from an action of the primary FAS complex to give 4-methylpentanoyl- and 5- and 4-methylhexanoyl-ACP intermediates. These ACP-tethered thioesters could be directly recruited by an unidentified KSI/II or FASI/II to perform three additional elongations and introduce the characteristic triene in analogy with the **A1**–**A4** upper chain biosynthesis. These observations are in agreement with the FabH involvement and suggest physiological cross-talk between polyketide and fatty acid biosynthesis.

CHC-CoA is not only the substrate for the polyketide synthase AsuC3,C4 in **A1** upper chain assembly but is also recruited by the FAS complex and assembled into ω -cyclohexyl fatty acids, which account for 3.1% of total cellular fatty acids in *S. nodosus* subsp. *asukaensis* (7). The CHC-CoA utilization to form asukamycin **A1** and ω -cyclohexyl fatty acids does not occur in a fixed ratio, as **A1** was increased to more than 80% of total asukamycins, whereas ω -cyclohexyl fatty acids were kept under 25% of total fatty acids upon feeding excess cyclohexanecarboxylic acid (7). Besides the distinct substrate specificities of FabH and AsuC3,C4, this could also be the result of type II thioesterase AsuC15 action to release the tethered cyclohexylpropanoate from the FAS-ACP and allow the recruitment of more branched chain acyl-CoA starters, as the percentage of

ω -cyclohexyl fatty acids was increased 5-fold in the *asuC15* mutant. The cellular membrane fluidity is probably affected by variations in the content of ω -cyclohexyl fatty acids, changing the phase transition temperature, as observed for several thermo-acidophilic bacteria, which may contain up to 90% of ω -cyclohexyl fatty acids (18, 19, 61). Thus AsuC15 could suppress excess ω -cyclohexyl fatty acid formation and help to maintain membrane homeostasis and structural integrity, particularly when the cellular level of CHC-CoA is rising. Evidently, AsuC15 can also discharge the CHC-acyl intermediate from AsuC5-ACP to enhance the production of congeners **A2**–**A4**, as the *asuC15* mutant predominantly accumulates **A1** rather than an equal amount of **A1** and **A2**–**A4** observed in the wild type.

AsuD1, D2, and D3 are necessary and sufficient for the assembly and attachment of the C₅N moiety to form protoasukamycin. AsuD2 bears a Ser⁸³ in the position of the conserved Thr⁸³ of ALAS. The distinct role of AsuD2-Ser⁸³ in C₅N moiety formation was confirmed by expression of AsuD2-S83T, which failed to complement the *asuD2* mutant but sustained the ability to form 5-ALA in the *gtr* mutant of *S. coelicolor*. The fact that 5-ALA is a precursor of the C₅N unit but does not complement the *asuD2* mutation shows that *asuD2* has a second function in C₅N formation (13, 15, 16). The nascent pyridoxal phosphate-bound 5-ALA or possibly a predecarboxylation intermediate 2-amino-3-oxoadipate could be retained on AsuD2 and carboxyl-activated by the action of the CoA ligase AsuD3, followed by cyclization catalyzed by AsuD2 (Fig. 5). The dual role of AsuD2 is also supported by the results of the heterologous expression of *asuD1*–*D3* to produce the C₅N unit in the absence of any other candidate cyclase gene in *S. lividans*. The amide synthase AsuD1 is responsible for the attachment of the C₅N unit to the C terminus of the lower chain. As all the assumed intermediates in this process are relatively unstable (10), AsuD1, D2, and D3 might work together to secure the formation of protoasukamycin.

Both one-step dioxygenase and two-step monooxygenase mechanisms have been proposed for epoxyquinol formation (1, 10, 11). The present study resolves this issue as two monooxygenations, first 4-hydroxylation of protoasukamycin **C1** by AsuE1 and AsuE2, followed by epoxidation of the resulting quinol **D1** by AsuE3 to form asukamycin **A1** (Fig. 5). As AsuE3 specifically acts on the quinol moiety but not a phenolic structure, the protoasukamycin 4-hydroxylation is a prerequisite for epoxidation. Notably, replacement of the upper chain by an acetyl group or the absence of the C₅N moiety has no impact on epoxyquinol formation as evidenced by **A8** and **A1a**, respectively.

It seems that asukamycin biosynthesis has evolved through multiple horizontal gene transfer events and possibly an extensive genomic rearrangement in *S. nodosus* subsp. *asukaensis*. The biosynthetic genes involved in C₅N moiety and CHC-CoA assembly are closely positioned and appear to be co-transcribed, but many other functionally related *asu* genes are not organized in any apparent order. Recently, the λ -Red recombination system has been extended to heterologous expression (23–25). Taking advantage of the shared vector and overlapping inserts, we simplified this system and assembled two cos-

mids in a single step by skipping the PCR cloning and multiple “stitching” processes (Fig. 3). Since the linearized cosmids are unable to replicate, the circular recombinant pART1361 could propagate and form colonies under antibiotic selection. This straightforward recombination approach is particularly useful to examine cloned genes and provides a convenient platform for further gene manipulations. For example, a reliable yield of 4-hydroxyprotoasukamycin **D1** was obtained in *S. lividans* carrying the pART1361E3 by replacing *asuE3* with a spectinomycin resistance gene.

Acknowledgments—We are grateful to C. Khosla (*S. lividans* K4-114) and John Innes Center (λ -Red recombination kit) for the gifts of strains and plasmids. We thank Drs. J. Chen, G. Henderson, and T. K. Weld-eghiorghis for assistance with mass spectral and NMR analyses and M. Saboori for the *asuC2* analysis. We thank the anonymous reviewers for constructive comments.

REFERENCES

- Sattler, I., Thiericke, R., and Zeeck, A. (1998) *Nat. Prod. Rep.* **15**, 221–240
- Shipley, P. R., Donnelly, C. C., Le, C. H., Bernauer, A. D., and Klegeris, A. (2009) *Int. J. Mol. Med.* **24**, 711–715
- Bernier, M., Kwon, Y. K., Pandey, S. K., Zhu, T. N., Zhao, R. J., Maciuk, A., He, H. J., Decabo, R., and Kole, S. (2006) *J. Biol. Chem.* **281**, 2551–2561
- Zheng, Z. H., Dong, Y. S., Zhang, H., Lu, X. H., Ren, X., Zhao, G., He, J. G., and Si, S. Y. (2007) *J. Enzyme Inhib. Med. Chem.* **22**, 43–49
- Kakinuma, K., Ikekawa, N., Nakagawa, A., and Omura, S. (1979) *J. Am. Chem. Soc.* **101**, 3402–3404
- Omura, S., Kitao, C., Tanaka, H., Oiwa, R., Takahashi, Y., Nakagawa, A., Shimada, M., and Iwai, Y. (1976) *J. Antibiot.* **29**, 876–881
- Hu, Y. D., and Floss, H. G. (2006) *Heterocycles* **69**, 133–149
- Hu, Y., and Floss, H. G. (2001) *J. Antibiot.* **54**, 340–348
- Hu, Y. D., Melville, C. R., Gould, S. J., and Floss, H. G. (1997) *J. Am. Chem. Soc.* **119**, 4301–4302
- Hu, Y. D., and Floss, H. G. (2004) *J. Am. Chem. Soc.* **126**, 3837–3844
- Thiericke, R., Zeeck, A., Nakagawa, A., Omura, S., Herrold, R. E., Wu, S. T. S., Beale, J. M., and Floss, H. G. (1990) *J. Am. Chem. Soc.* **112**, 3979–3987
- Cropp, T. A., Wilson, D. J., and Reynolds, K. A. (2000) *Nat. Biotechnol.* **18**, 980–983
- Beale, J. M., Lee, J. P., Nakagawa, A., Omura, S., and Floss, H. G. (1986) *J. Am. Chem. Soc.* **108**, 331–332
- Ostash, B., Saghatelian, A., and Walker, S. (2007) *Chem. Biol.* **14**, 257–267
- Petríček, M., Petricková, K., Havlíček, L., and Felsberg, J. (2006) *J. Bacteriol.* **188**, 5113–5123
- Nakagawa, A., Wu, T. S., Keller, P. J., Lee, J. P., Omura, S., and Floss, H. G. (1985) *J. Chem. Soc. Chem. Comm.* 519–521
- Thiericke, R., Zeeck, A., Robinson, J. A., Beale, J. M., and Floss, H. G. (1989) *J. Chem. Soc. Chem. Comm.* 402–403
- Kaneda, T. (1991) *Microbiol. Rev.* **55**, 288–302
- Zhang, Y. M., and Rock, C. O. (2008) *Nat. Rev. Microbiol.* **6**, 222–233
- Datsenko, K. A., and Wanner, B. L. (2000) *Proc. Natl. Acad. Sci. U.S.A.* **97**, 6640–6645
- Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F., and Hopwood, D. A. (2000) *Practical Streptomyces Genetics*, The John Innes Foundation, Norwich, UK
- Suzuki, H., Ohnishi, Y., Furusho, Y., Sakuda, S., and Horinouchi, S. (2006) *J. Biol. Chem.* **281**, 36944–36951
- Binz, T. M., Wenzel, S. C., Schnell, H. J., Bechthold, A., and Müller, R. (2008) *ChemBioChem* **9**, 447–454
- Wolpert, M., Heide, L., Kammerer, B., and Gust, B. (2008) *ChemBioChem* **9**, 603–612
- Hu, Y., Phelan, V. V., Farnet, C. M., Zazopoulos, E., and Bachmann, B. O. (2008) *ChemBioChem* **9**, 1603–1608
- Pfennig, F., Schauwecker, F., and Keller, U. (1999) *J. Biol. Chem.* **274**, 12508–12516
- Zhou, Z., Lai, J. R., and Walsh, C. T. (2007) *Proc. Natl. Acad. Sci. U.S.A.* **104**, 11621–11626
- Ferreras, J. A., Stirrett, K. L., Lu, X., Ryu, J. S., Soll, C. E., Tan, D. S., and Quadri, L. E. (2008) *Chem. Biol.* **15**, 51–61
- Hertweck, C. (2009) *Angew. Chem. Int. Ed. Engl.* **48**, 4688–4716
- Sattely, E. S., Fischbach, M. A., and Walsh, C. T. (2008) *Nat. Prod. Rep.* **25**, 757–793
- Huang, W., Jia, J., Edwards, P., Dehesh, K., Schneider, G., and Lindqvist, Y. (1998) *EMBO J.* **17**, 1183–1191
- Olsen, J. G., Kadziola, A., von Wettstein-Knowles, P., Siggaard-Andersen, M., Lindqvist, Y., and Larsen, S. (1999) *FEBS Lett.* **460**, 46–52
- Tang, Y., Lee, H. Y., Tang, Y., Kim, C. Y., Mathews, I., and Khosla, C. (2006) *Biochemistry* **45**, 14085–14093
- Cohen-Gonsaud, M., Ducasse, S., Hoh, F., Zerbib, D., Labesse, G., and Quemard, A. (2002) *J. Mol. Biol.* **320**, 249–261
- Sacco, E., Covarrubias, A. S., O'Hare, H. M., Carroll, P., Eynard, N., Jones, T. A., Parish, T., Daffé, M., Bäckbro, K., and Quémar, A. (2007) *Proc. Natl. Acad. Sci. U.S.A.* **104**, 14628–14633
- Palaniappan, N., Kim, B. S., Sekiyama, Y., Osada, H., and Reynolds, K. A. (2003) *J. Biol. Chem.* **278**, 35552–35557
- Pan, H., Tsai, S., Meadows, E. S., Miercke, L. J., Keatinge-Clay, A. T., O'Connell, J., Khosla, C., and Stroud, R. M. (2002) *Structure* **10**, 1559–1568
- Tang, Y., Lee, T. S., Kobayashi, S., and Khosla, C. (2003) *Biochemistry* **42**, 6588–6595
- Astner, I., Schulze, J. O., van den Heuvel, J., Jahn, D., Schubert, W. D., and Heinz, D. W. (2005) *EMBO J.* **24**, 3166–3177
- Gerber, R., Lou, L., and Du, L. C. (2009) *J. Am. Chem. Soc.* **131**, 3148–3149
- Hanada, K. (2003) *Biochim. Biophys. Acta* **1632**, 16–30
- Webster, S. P., Alexeev, D., Campopiano, D. J., Watt, R. M., Alexeeva, M., Sawyer, L., and Baxter, R. L. (2000) *Biochemistry* **39**, 516–528
- Pacholec, M., Freil Meyers, C. L., Oberthür, M., Kahne, D., and Walsh, C. T. (2005) *Biochemistry* **44**, 4949–4956
- Schmutz, E., Steffensky, M., Schmidt, J., Porzel, A., Li, S. M., and Heide, L. (2003) *Eur. J. Biochem.* **270**, 4413–4419
- Yu, T. W., Bai, L., Clade, D., Hoffmann, D., Toelzer, S., Trinh, K. Q., Xu, J., Moss, S. J., Leistner, E., and Floss, H. G. (2002) *Proc. Natl. Acad. Sci. U.S.A.* **99**, 7968–7973
- Vineis, P., Bartsch, H., Caporaso, N., Harrington, A. M., Kadlubar, F. F., Landi, M. T., Malaveille, C., Shields, P. G., Skipper, P., Talaska, G., and Tannenbaum, S. R. (1994) *Nature* **369**, 154–156
- Cole, L. J., Gatti, D. L., Entsch, B., and Ballou, D. P. (2005) *Biochemistry* **44**, 8047–8058
- Kirchner, U., Westphal, A. H., Müller, R., and van Berkel, W. J. (2003) *J. Biol. Chem.* **278**, 47545–47553
- van der Werf, M. J., Swarts, H. J., and de Bont, J. A. (1999) *Appl. Environ. Microbiol.* **65**, 2092–2102
- Claxton, H. B., Akey, D. L., Silver, M. K., Admiraal, S. J., and Smith, J. L. (2009) *J. Biol. Chem.* **284**, 5021–5029
- Koglin, A., Löhr, F., Bernhard, F., Rogov, V. V., Frueh, D. P., Strieter, E. R., Mofid, M. R., Güntert, P., Wagner, G., Walsh, C. T., Marahiel, M. A., and Dötsch, V. (2008) *Nature* **454**, 907–911
- Kotowska, M., Pawlik, K., Smulczyk-Krawczynszyn, A., Bartosz-Bechowski, H., and Kuczek, K. (2009) *Appl. Environ. Microbiol.* **75**, 887–896
- Kim, B. S., Cropp, T. A., Beck, B. J., Sherman, D. H., and Reynolds, K. A. (2002) *J. Biol. Chem.* **277**, 48028–48034
- Yeh, E., Kohli, R. M., Bruner, S. D., and Walsh, C. T. (2004) *ChemBioChem* **5**, 1290–1293
- Song, F., Zhuang, Z., Finci, L., Dunaway-Mariano, D., Kniewel, R., Buglino, J. A., Solorzano, V., Wu, J., and Lima, C. D. (2006) *J. Biol. Chem.* **281**, 11028–11038
- Kotaka, M., Kong, R., Qureshi, I., Ho, Q. S., Sun, H., Liew, C. W., Goh, L. P., Cheung, P., Mu, Y., Lescar, J., and Liang, Z. X. (2009) *J. Biol. Chem.* **284**, 15739–15749

Asukamycin Biosynthetic Pathway

57. Nasser, W., and Reverchon, S. (2007) *Anal. Bioanal. Chem.* **387**, 381–390
58. Ramos, J. L., Martínez-Bueno, M., Molina-Henares, A. J., Terán, W., Watanabe, K., Zhang, X., Gallegos, M. T., Brennan, R., and Tobes, R. (2005) *Microbiol. Mol. Biol. Rev.* **69**, 326–356
59. Groban, E. S., Clarke, E. J., Salis, H. M., Miller, S. M., and Voigt, C. A. (2009) *J. Mol. Biol.* **390**, 380–393
60. Kitani, S., Iida, A., Izumi, T. A., Maeda, A., Yamada, Y., and Nihira, T. (2008) *Gene* **425**, 9–16
61. Simbahan, J., Drijber, R., and Blum, P. (2004) *Int. J. Syst. Evol. Microbiol.* **54**, 1703–1707
62. Zhang, W., Bolla, M. L., Kahne, D., and Walsh, C. T. (2010) *J. Am. Chem. Soc.* **132**, 6402–6411

Microbiology:
**Biochemical and Genetic Insights into
Asukamycin Biosynthesis**

MICROBIOLOGY

Zhe Rui, Katerina Petřícková, Frantisek
Skanta, Stanislav Pospíšil, Yanling Yang,
Chung-Yung Chen, Shih-Feng Tsai, Heinz G.
Floss, Miroslav Petřícek and Tin-Wein Yu
J. Biol. Chem. 2010, 285:24915-24924.
doi: 10.1074/jbc.M110.128850 originally published online June 3, 2010

Access the most updated version of this article at doi: [10.1074/jbc.M110.128850](http://dx.doi.org/10.1074/jbc.M110.128850)

Find articles, minireviews, Reflections and Classics on similar topics on the [JBC Affinity Sites](http://www.jbc.org/).

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

Supplemental material:

<http://www.jbc.org/content/suppl/2010/06/03/M110.128850.DC1.html>

This article cites 59 references, 21 of which can be accessed free at
<http://www.jbc.org/content/285/32/24915.full.html#ref-list-1>